26
|
Antinori S, Ridolfo AL, Fasan M, Magni C, Galimberti L, Milazzo L, Sollima S, Adorni F, Giuliani G, Galli M, Corbellino M, Parravicini C. AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy. HIV Med 2009; 10:6-11. [DOI: 10.1111/j.1468-1293.2008.00645.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Cesari M, Caramma I, Antinori S, Viganò OV, Galli M, Milazzo L. Impact of hyperglycemia and cholesterol levels on the outcome of hepatitis C treatment in HIV/HCV co-infected patients. J Int AIDS Soc 2008. [DOI: 10.1186/1758-2652-11-s1-p274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
28
|
Milazzo L, Trovati S, Pedenovi S, De Angelis S, Parravicini C. Recurrent herpes simplex virus (HSV) eyelid infection in an HIV-1 infected patient. Infection 2007; 35:393-4. [PMID: 17882358 DOI: 10.1007/s15010-007-6336-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2006] [Accepted: 02/26/2007] [Indexed: 11/26/2022]
|
29
|
Meroni L, Milazzo L, Menzaghi B, Mazzucchelli R, Mologni D, Morelli P, Broggini V, Adorni F, Galli M, Riva A. Altered expression of the tetraspanin CD81 on B and T lymphocytes during HIV-1 infection. Clin Exp Immunol 2007; 147:53-9. [PMID: 17177963 PMCID: PMC1810438 DOI: 10.1111/j.1365-2249.2006.03250.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
CD81 is a member of the tetraspan superfamily and plays a role in immune responses and in hepatitis C virus (HCV) pathogenesis. We analysed CD81 cell surface and mRNA expression in different lymphocytic subpopulations in human immunodeficiency virus (HIV)-1, HCV and dually infected subjects. CD81 cell surface expression was evaluated with fluorescence activated cell sorter (FACS) analysis; mRNA quantification was performed with semiquantitative polymerase chain reaction (PCR). CD81 cell surface expression on CD4(+) T lymphocytes was significantly different by analysis of variance (anova) test (P < 0.001), with reduced expression in HIV-1(+) patients. In B lymphocytes, higher cell surface expression was present in HIV-1, in HCV and in dually infected subjects compared to healthy controls. CD81 expression on B lymphocytes showed a positive correlation with plasma HIV-RNA. CD81 mRNA levels in B lymphocytes were significantly higher in HIV-1(+) patients compared to healthy controls. The potential consequence of the down-regulation of CD81 in CD4(+) cells during HIV-1 infection in conjunction with diverted CD28, CD4 and CD3 expression is the disruption of T cell function. Increased CD81 expression on B lymphocytes might explain the higher prevalence of lymphoproliferative disorders in HIV-1 and HCV infection. Up-regulation of CD81 mRNA on CD4(+) T cells indicates that down-regulation of CD81 occurs at the post-transcriptional/translational level.
Collapse
|
30
|
Link JM, Yager PM, Anjos JC, Bediaga I, Castromonte C, Machado AA, Magnin J, Massafferi A, de Miranda JM, Pepe IM, Polycarpo E, dos Reis AC, Carrillo S, Casimiro E, Cuautle E, Sánchez-Hernández A, Uribe C, Vázquez F, Agostino L, Cinquini L, Cumalat JP, O'Reilly B, Segoni I, Stenson K, Butler JN, Cheung HWK, Chiodini G, Gaines I, Garbincius PH, Garren LA, Gottschalk E, Kasper PH, Kreymer AE, Kutschke R, Wang M, Benussi L, Bertani M, Bianco S, Fabbri FL, Pacetti S, Zallo A, Reyes M, Cawlfield C, Kim DY, Rahimi A, Wiss J, Gardner R, Kryemadhi A, Chung YS, Kang JS, Ko BR, Kwak JW, Lee KB, Cho K, Park H, Alimonti G, Barberis S, Boschini M, Cerutti A, D'Angelo P, DiCorato M, Dini P, Edera L, Erba S, Inzani P, Leveraro F, Malvezzi S, Menasce D, Mezzadri M, Milazzo L, Moroni L, Pedrini D, Pontoglio C, Prelz F, Rovere M, Sala S, Davenport TF, Arena V, Boca G, Bonomi G, Gianini G, Liguori G, Pegna DL, Merlo MM, Pantea D, Ratti SP, Riccardi C, Vitulo P, Göbel C, Hernandez H, Lopez AM, Mendez H, Paris A, Quinones J, Ramirez JE, Zhang Y, Wilson JR, Handler T, Mitchell R, Engh D, Hosack M, Johns WE, Luiggi E, Moore JE, Nehring M, Sheldon PD, Vaandering EW, Webster M, Sheaff M. Measurement of the D(s)+ lifetime. PHYSICAL REVIEW LETTERS 2005; 95:052003. [PMID: 16090867 DOI: 10.1103/physrevlett.95.052003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2005] [Indexed: 05/03/2023]
Abstract
A high statistics measurement of the D(s)+ lifetime from the Fermilab fixed-target FOCUS photoproduction experiment is presented. We describe the analysis of the two decay modes, D(s)+ --> phi(1020)pi+ and D(s)+ -->K*(892)0K+, used for the measurement. The measured lifetime is 507.4 +/- 5.5(stat) +/- 5.1(syst) fs using 8961 +/- 105 D(s)+ --> phi(1020)pi+ and 4680 +/- 90 D(s)+ --> K*(892)0K+ decays. This is a significant improvement over the present world average.
Collapse
|
31
|
Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Scalise G, Cesare SD, Chiodo F, Verucchi G, Farci P, Serra G, Sagnelli E, Nacca C, Ferraro T, Scerbo A, Santoro D, Pusterla L, Viganò P, Magnani C, Ghinelli F, Sighinolfi L, Vigevani G, Pastecchia C, Moroni M, Milazzo L, Esposito R, Borghi V, Piccinino F, Filippini P, Cadrobbi P, Sattin A, Ferrari C, Antoni AD, Stagni G, Francisci D, Petrelli E, Alberici F, Sacchini D, Zauli T, Donà DD, Arlotti M, Mori F, Marranconi F, Caramello P, Lipani F, Soranzo ML, Macor A, Vaglia A, Rossi MC, Grossi P, Tambini R, De Lalla F, Tositti G. Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart. Antivir Ther 2005. [DOI: 10.1177/135965350501000215] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Chronic hepatitis C is common and aggressive in HIV-positive patients, so the development of a well-tolerated HCV therapy is a priority. We evaluated the efficacy and safety of pegylated interferon α2b (PEG-IFN) plus ribavirin (RBV) versus PEG-IFN monotherapy in HIV/HCV-coinfected patients undergoing highly active antiretroviral therapy (HAART), and analysed the predictive factors of response. Methods An Italian, multicentre, open-label trial including 135 coinfected patients, randomized to PEG-IFN 1.5 μg/kg/week plus RBV 400 mg twice daily ( n=69, arm A) or PEG-IFN 1.5 μg/kg/week ( n=66, arm B) for 48 weeks. We assessed the predictive values of early virological response (EVR) at week 8 (HCV-RNA drop >2 log10 compared with baseline or undetectable levels) on sustained virological response (SVR). Results Fifty-five patients (28 from arm A and 27 from arm B) completed 48 weeks of therapy. At the end of treatment, 20/28 patients in arm A and 11/27 in arm B had HCV-RNA <50 IU/ml. In a per-protocol analysis, SVR was reached by 54% of patients in arm A (genotype 2–3, 11/16; genotype 1–4, 4/12) and 22% in arm B (genotype 2–3, 3/15; genotype 1–4, 3/12). In an intention-to-treat analysis, the SVR was 22% in arm A (genotype 2–3, 11/32; genotype 1–4, 4/37) versus 9% in arm B (genotype 2–3, 3/32; genotype 1–4, 3/34). The best predictors of SVR were the use of combination therapy, infection with HCV genotype 3 versus genotype 1, and EVR at week 8. Thirty patients (15 from arm A and 15 from arm B) dropped out of the trial prematurely due to side effects. The positive predictive value of EVR at week 8 was 65%, the negative predictive value was 86%. Conclusions PEG-IFN plus RBV can be considered a solid option for the treatment of HIV/HCV-coinfected patients. The key to successfully improving efficacy is strong compliance through strict overall patient monitoring, in order to best manage drug toxicity. EVR assessment at week 8 may become a useful stategy in the management of therapy.
Collapse
|
32
|
Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, Morsica G, Pizzaferri P, Ladisa N, Sighinolfi L, Chiodera A, Solmone M, Lalle E, Ippolito G, Monforte AD, Ancarani F, Antinori A, Antonucci G, Bonasso M, Bruno R, Capobianchi MR, Cargnel A, Cozzi-Lepri A, d'Arminio Monforte A, Luca AD, Galli M, Gennero L, Girardi E, Lipani F, Marino N, Milazzo L, Morsica G, Narciso P, Pizzaferri P, Puoti M, Santantonio T, Verucchi G, Montroni M, Scalise G, Braschi MC, Prete MSD, Tirelli U, Cinelli R, Pastore G, Ladisa N, Suter GMBF, Arici C, Chiodo F, Colangeli V, Fiorini C, Coronado O, Carosi G, Cadeo GP, Torti C, Minardi C, Bertelli D, Rizzardini G, Migliorino G, Manconi PE, Piano P, Ferraro T, Scerbo A, Pizzigallo E, D'Alessandro M, Santoro D, Pusterla L, Carnevale G, Galloni D, Viganò P, Mena M, Ghinelli F, Sighinolfi L, Leoncini F, Mazzotta F, Pozzi M, Caputo SL, Angarano G, Grisorio B, Saracino A, Ferrara S, Grima P, Tundo P, Pagano G, Cassola G, Alessandrini A, Piscopo R, Toti M, Chigiotti S, Soscia F, Tacconi L, Orani A, Perini P, Scasso A, Vincenti A, Chiodera F, Castelli P, Scalzini A, Fibbia G, Moroni M, Lazzarin A, Cargnel A, Vigevani GM, Caggese L, Monforte AD, Repetto D, Novati R, Galli A, Merli S, Pastecchia C, Moioli MC, Esposito R, Mussini C, Abrescia N, Chirianni A, Izzo CM, Piazza M, Marco MD, Viglietti R, Manzillo E, Graf M, Colomba A, Abbadessa V, Prestileo T, Mancuso S, Ferrari C, Pizzaferri P, Filice G, Minoli L, Bruno R, Novati S, Baldelli F, Tinca M, Petrelli E, Cioppi A, Alberici F, Ruggieri A, Menichetti F, Martinelli C, Stefano CD, Gala AL, Ballardini G, Briganti E, Magnani G, Ursitti MA, Arlotti M, Ortolani P, Cauda R, Dianzani F, Ippolito G, Antinori A, Antonucci G, D'Elia S, Narciso P, Petrosillo N, Vullo V, Luca AD, Giambenedetti SD, Zaccarelli M, Acinapura R, Longis PD, Ciardi M, D'Offizi G, Trotta MP, Noto P, Lichtner M, Capobianchi MR, Girardi E, Pezzotti P, Rezza G, Mura MS, Mannazzu M, Resta F, Loso K, Caramello P, Sinicco A, Soranzo ML, Orofino G, Sciandra M, Bonasso M, Grossi PA, Basilico C, Poggio A, Bottari G, Raise E, Pasquinucci S, Lalla FD, Tositti G, Lepri AC. Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals. Antivir Ther 2005. [DOI: 10.1177/135965350501000108] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The prognostic role of GB virus type C (GBV-C) viraemia in HIV-infected subjects treated with highly active antiretroviral therapy (HAART) is still undefined, The aim of this analysis is to assess the relationship between GBV-C infection and response to antiretroviral therapy among HIV-infected subjects initiating HAART when antiretroviral-naive. A prospective, observational study of 400 HIV-infected patients with measurements of GBV-C RNA, hepatitis C virus (HCV) antibodies and HCV RNA determined from plasma stored prior to HAART initiation, Time to virological (achieving HIV RNA ≤500 copies/ml) and immunological success (a CD4+ count increase of ≥200cells/μl), and the time to virological relapse (confirmed HIV RNA >500 copies/ml) were assessed by Kaplan-Meier methods and Cox proportional hazard regression model. Of the subjects, 117 (29.3%) were GBV-C positive and, overall, 351 (87.8%) patients achieved virological success, After controlling for a number of confounders including HCV RNA, GBV-C viraemic patients experienced a significantly lower risk of HIV rebound than those who were GBV-C negative [relative hazard (RH)=0.56, 95% CI: 0.34–0.93, P=0.03], Conversely, the probability of achieving initial virological success or CD4+ count response after HAART did not differ between GBV-C-negative and -positive subjects, These results suggest that GBV-C coinfection may play a role in determining the rate of HIV rebound possibly by competing with HIV replication after HIV load has been successfully suppressed by HAART.
Collapse
|
33
|
Puoti M, Cozzi-Lepri A, Ancarani F, Bruno R, Ambu S, Ferraro T, Tundo P, Santantonio T, Toti M, Bonasso M, Monforte AD, Ancarani F, Antonucci G, Bonasso M, Bruno R, Cozzi-Lepri A, Monforte AD, Luca AD, Galli M, Gennero L, Girardi E, Lipani F, Marino N, Milazzo L, Morsica G, Narciso P, Pizzaferri P, Puoti M, Santantonio T, Verucchi G, Montroni M, Scalise G, Zoli A, Prete MSD, Tirelli U, Di Gennaro G, Pastore G, Ladisa N, Minafra G, Suter F, Arici C, Chiodo F, Colangeli V, Fiorini C, Coronado O, Carosi G, Cadeo GP, Castelli F, Minardi C, Vangi D, Rizzardini G, Migliorino G, Manconi PE, Piano P, Ferraro T, Scerbo A, Pizzigallo E, D'Alessandro M, Santoro D, Pusterla L, Carnevale G, Galloni D, Viganò P, Mena M, Ghinelli F, Sighinolfi L, Leoncini F, Mazzotta F, Pozzi M, Lo Caputo S, Angarano G, Grisorio B, Ferrara S, Grima P, Tundo P, Pagano G, Piersantelli N, Alessandrini A, Piscopo R, Toti M, Chigiotti S, Soscia F, Tacconi L, Orani A, Perini P, Scasso A, Vincenti A, Chiodera F, Castelli P, Scalzini A, Fibbia G, Moroni M, Lazzarin A, Cargnel A, Vigevani GM, Caggese L, d'Arminio Monforte A, Repetto D, Novati R, Galli A, Merli S, Pastecchia C, Moioli MC, Esposito R, Mussini C, Abrescia N, Chirianni A, Izzo C, Piazza M, De Marco M, Montesarchio V, Manzillo E, Graf M, Colomba A, Abbadessa V, Prestileo T, Mancuso S, Ferrari C, Pizzaferri P, Filice G, Minoli L, Bruno R, Novati S, Balzelli F, Loso K, Petrelli E, Cioppi A, Alberici F, Ruggieri A, Menichetti F, Martinelli C, De Stefano C, La Gala A, Ballardini G, Briganti E, Magnani G, Ursitti MA, Arlotti M, Ortolani P, Ortona L, Dianzani F, Ippolito G, Antinori A, Antonucci G, D'Elia S, Narciso P, Petrosillo N, Vullo V, De Luca A, Del Forno L, Zaccarelli M, Acinapura R, De Longis P, Ciardi M, D'Offizi G, Trotta MP, Noto P, Lichtner M, Capobianchi MR, Girardi E, Pezzotti P, Rezza G, Mura MS, Mannazzu M, Caramello P, Sinicco A, Soranzo ML, Gennero L, Sciandra M, Bonasso M, Grossi PA, Basilico C, Poggio A, Bottari G, Raise E, Pasquinucci S, De Lalla F, Tositti G, Resta F, Chimienti A, Cozzi-Lepri A. The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug? Antivir Ther 2004. [DOI: 10.1177/135965350400900506] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [–81.1 mU/ml mean difference; 95% confidence intervals (95% CI): –30.3; –131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01–0.38, P=0.002] than those starting a lamivudine sparing-regimen.
Collapse
|
34
|
Ratti SP, Link J, Reyes M, Yager P, Anjos J, Bediaga I, Gobel C, Magnin J, Massafferri A, de Miranda J, Pepe I, dos Reis A, Carrillo S, Casimiro E, Sánchez-Hernández A, Uribe C, Vasquez F, Cinquini L, Cumalat J, O'Reilly B, Ramirez J, Vaandering E, Butler J, Gaines I, Garbincius P, Garren L, Gottschalk E, Kasper P, Kreymer A, Kuschke R, Bianco S, Fabbri F, Sarwar S, Zallo A, Cawlfield C, Kim D, Rahimi A, Wiss J, Gardner R, Kryemadhi A, Chung Y, Kang J, Ko B, Kwak J, Lee K, Park H, Alimonti G, Boschini M, Caccianiga B, D'Angelo P, DiCorato M, Dini P, Giammarchi M, Inzani P, Leveraro F, Malvezzi S, Menasce D, Mezzadri M, Milazzo L, Moroni L, Pedrini D, Pontoglio C, Preiz F, Rovere M, Sala S, Davenport T, Agostino L, Arena V, Boca G, Bonomi G, Gianini G, Liguori G, Merio M, Pantea D, Riccardi C, Segoni I, Vitulo P, Hernandez H, Lopez A, Mendez H, Mendez L, Montiel E, Olaya D, Paris A, Quinones J, Rivera C, Xiong W, Zhang Y, Wilson J, Cho K, Handler T, Mitchell R, Engh D, Hosack M, Johns W, Nehring M, Sheldon P, Stenson K, Webster M, Sheaff M. New results on c-baryons and a search for cc-baryons in FOCUS. ACTA ACUST UNITED AC 2003. [DOI: 10.1016/s0920-5632(02)01948-5] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Link JM, Reyes M, Yager PM, Anjos JC, Bediaga I, Göbel C, Magnin J, Massafferi A, de Miranda JM, Pepe IM, dos Reis AC, Carrillo S, Casimiro E, Cuautle E, Sánchez-Hernández A, Uribe C, Vazquez F, Agostino L, Cinquini L, Cumalat JP, O'Reilly B, Ramirez JE, Segoni I, Butler JN, Cheung HWK, Gaines I, Garbincius PH, Garren LA, Gottschalk E, Kasper PH, Kreymer AE, Kutschke R, Bianco S, Fabbri FL, Zallo A, Cawlfield C, Kim DY, Rahimi A, Wiss J, Gardner R, Kryemadhi A, Chung YS, Kang JS, Ko BR, Kwak JW, Lee KB, Park H, Alimonti G, Boschini M, D'Angelo P, DiCorato M, Dini P, Giammarchi M, Inzani P, Leveraro F, Malvezzi S, Menasce D, Mezzadri M, Milazzo L, Moroni L, Pedrini D, Pontoglio C, Prelz F, Rovere M, Sala S, Davenport TF, Arena V, Boca G, Bonomi G, Gianini G, Liguori G, Merlo MM, Pantea D, Ratti SP, Riccardi C, Vitulo P, Hernandez H, Lopez AM, Luiggi E, Mendez H, Mendez L, Mirles A, Montiel E, Olaya D, Paris A, Quinones J, Rivera C, Xiong W, Zhang Y, Wilson JR, Cho K, Handler T, Mitchell R, Engh D, Hosack M, Johns WE, Nehring M, Sheldon PD, Stenson K, Vaandering EW, Webster M, Sheaff M. A high statistics measurement of the Lambda(+)(c) lifetime. PHYSICAL REVIEW LETTERS 2002; 88:161801. [PMID: 11955226 DOI: 10.1103/physrevlett.88.161801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2002] [Indexed: 05/23/2023]
Abstract
A high statistics measurement of the Lambda(+)(c) lifetime from the Fermilab fixed-target FOCUS photoproduction experiment is presented. We describe the analysis technique with particular attention to the determination of the systematic uncertainty. The measured value of 204.6 +/- 3.4 (stat) +/- 2.5 (syst) fs from 8034 +/- 122 Lambda(+)(c)-->pK(-)pi(+) decays represents a significant improvement over the present world average.
Collapse
|
36
|
Link JM, Reyes M, Yager PM, Anjos JC, Bediaga I, Göbel C, Magnin J, Massafferri A, de Miranda JM, Pepe IM, dos Reis AC, Carrillo S, Casimiro E, Sánchez-Hernández A, Uribe C, Vázquez F, Cinquini L, Cumalat JP, O'Reilly B, Ramirez JE, Vaandering EW, Butler JN, Cheung HWK, Gaines I, Garbincius PH, Garren LA, Gottschalk E, Kasper PH, Kreymer AE, Kutschke R, Bianco S, Fabbri FL, Zallo A, Cawlfield C, Kim DY, Rahimi A, Wiss J, Gardner R, Kryemadhi A, Chung YS, Kang JS, Ko BR, Kwak JW, Lee KB, Park H, Alimonti G, Boschini M, D'Angelo P, DiCorato M, Dini P, Giammarchi M, Inzani P, Leveraro F, Malvezzi S, Menasce D, Mezzadri M, Milazzo L, Moroni L, Pedrini D, Pontoglio C, Prelz F, Rovere M, Sala S, Davenport TF, Agostino L, Arena V, Boca G, Bonomi G, Gianini G, Liguori G, Merlo MM, Pantea D, Ratti SP, Riccardi C, Segoni I, Vitulo P, Hernandez H, Lopez AM, Mendez H, Mendez L, Mirles A, Montiel E, Olaya D, Paris A, Quinones J, Rivera C, Xiong W, Zhang Y, Wilson JR, Cho K, Handler T, Mitchell R, Engh D, Hosack M, Johns WE, Nehring M, Sheldon PD, Stenson K, Webster M, Sheaff M. Search for CP violation in the decays D+--> K(S)pi+ and D+-->K(S)K+. PHYSICAL REVIEW LETTERS 2002; 88:041602. [PMID: 11801103 DOI: 10.1103/physrevlett.88.041602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/17/2001] [Indexed: 05/23/2023]
Abstract
A high-statistics sample of photoproduced charm from the FOCUS experiment has been used to search for direct CP violation in the decay rates for D+-->K(S)pi+ and D+-->K(S)K+. We have measured the following asymmetry parameters relative to D+-->K-pi+pi+: A(CP)(K(S)pi+) = (-1.6+/-1.5+/-0.9)%, A(CP)(K(S)K+) = (+6.9+/-6.0+/-1.5)%, and A(CP)(K(S)K+) = (+7.1+/-6.1+/-1.2)% relative to D+-->K(S)pi+. We have also measured the relative branching ratios and found Gamma(D+-->K(0)pi+)/Gamma(D+-->K-pi+pi+) = (30.60+/-0.46+/-0.32)%, Gamma(D+-->K(0)K+)/Gamma(D+-->K-pi+pi+) = (6.04+/-0.35+/-0.30)%, and Gamma(D+-->K(0)K+)/Gamma(D+-->K(0)pi+) = (19.96+/-1.19+/-0.96)%.
Collapse
|
37
|
Link JM, Reyes M, Yager PM, Anjos JC, Bediaga I, Göbel C, Magnin J, Massafferi A, de Miranda JM, Pepe IM, dos Reis AC, Simão FR, Carrillo S, Casimiro E, Sánchez-Hernández A, Uribe C, Vázquez F, Cinquini L, Cumalat JP, O'Reilly B, Ramirez JE, Vaandering EW, Butler JN, Cheung HW, Gaines I, Garbincius PH, Garren LA, Gottschalk E, Kasper PH, Kreymer AE, Kutschke R, Bianco S, Fabbri FL, Sarwar S, Zallo A, Cawlfield C, Kim DY, Rahimi A, Wiss J, Gardner R, Chung YS, Kang JS, Ko BR, Kwak JW, Lee KB, Park H, Alimonti G, Boschini M, Caccianiga B, D'Angelo P, DiCorato M, Dini P, Giammarchi M, Inzani P, Leveraro F, Malvezzi S, Menasce D, Mezzadri M, Milazzo L, Moroni L, Pedrini D, Pontoglio C, Prelz F, Rovere M, Sala A, Sala S, Davenport TF, Agostino L, Arena V, Boca G, Bonomi G, Gianini G, Liguori G, Merlo M, Pantea D, Ratti SP, Riccardi C, Segoni I, Viola L, Vitulo P, Hernandez H, Lopez AM, Mendez H, Mendez L, Mirles A, Montiel E, Olaya D, Paris A, Quinones J, Rivera C, Xiong W, Zhang Y, Wilson JR, Cho K, Handler T, Engh D, Hosack M, Johns WE, Nehring M, Sheldon PD, Stenson K, Webster M, Sheaff M. Measurement of the branching ratios of D(+) and D(+)(s) hadronic decays to four-body final states containing a K(S). PHYSICAL REVIEW LETTERS 2001; 87:162001. [PMID: 11690200 DOI: 10.1103/physrevlett.87.162001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/12/2001] [Indexed: 05/23/2023]
Abstract
We have studied hadronic four-body decays of D(+) and D(+)(s) mesons with a K(S) in the final state using data recorded during the 1996-1997 fixed-target run of the Fermilab high energy photoproduction experiment FOCUS. We report a new branching ratio measurement of gamma(D(+)-->K(S)K-pi(+)pi(+))/gamma(D(+)-->K(S)pi(+)pi(+)pi(-)) = 0.0768+/-0.0041+/-0.0032. We make the first observation of three new decay modes with branching ratios gamma(D(+)-->K(S)K+pi(+)pi(-))/gamma(D(+)-->K(S)pi(+)pi(+)pi(-)) = 0.0562+/-0.0039+/-0.0040, gamma(D(+)-->K(S)K+K-pi(+))/gamma(D(+)-->K(S)pi(+)pi(+)pi(-)) = 0.0077+/-0.0015+/-0.0009, and gamma(D(+)(s)-->K(S)K+pi(+)pi(-))/gamma(D(+)(s)-->K(S)K-pi(+)pi(+)) = 0.586+/-0.052+/-0.043, where in each case the first error is statistical and the second error is systematic.
Collapse
|
38
|
Link JM, Reyes M, Yager PM, Anjos JC, Bediaga I, Göbel C, Magnin J, Massafferi A, de Miranda JM, Pepe IM, dos Reis AC, Simão FR, Carrillo S, Casimiro E, Sánchez-Hernández A, Uribe C, Vazquez F, Cinquini L, Cumalat JP, O'Reilly B, Ramirez JE, Vaandering EW, Butler JN, Cheung HW, Gaines I, Garbincius PH, Garren LA, Gottschalk E, Kasper PH, Kreymer AE, Kutschke R, Bianco S, Fabbri FL, Sarwar S, Zallo A, Cawlfield C, Kim DY, Rahimi A, Wiss J, Gardner R, Chung YS, Kang JS, Ko BR, Kwak JW, Lee KB, Park H, Alimonti G, Boschini M, Caccianiga B, D'Angelo P, DiCorato M, Dini P, Giammarchi M, Inzani P, Leveraro F, Malvezzi S, Menasce D, Mezzadri M, Milazzo L, Moroni L, Pedrini D, Pontoglio C, Prelz F, Rovere M, Sala A, Sala S, Davenport TF, Agostino L, Arena V, Boca G, Bonomi G, Gianini G, Liguori G, Merlo M, Pantea D, Ratti SP, Riccardi C, Segoni I, Viola L, Vitulo P, Hernandez H, Lopez AM, Mendez H, Mendez L, Mirles A, Montiel E, Olaya D, Paris A, Quinones J, Rivera C, Xiong W, Zhang Y, Wilson JR, Cho K, Handler T, Engh D, Hosack M, Johns WE, Nehring MS, Sheldon PD, Stenson K, Webster MS, Sheaff M. Study of the decay D0 --> K+pi-. PHYSICAL REVIEW LETTERS 2001; 86:2955-2958. [PMID: 11290081 DOI: 10.1103/physrevlett.86.2955] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2000] [Indexed: 05/23/2023]
Abstract
Using a large sample of photoproduced charm mesons from the FOCUS experiment at Fermilab (FNAL-E831), we observe the decay D0-->K+pi- with a signal yield of 149+/-31 events compared to a similarly cut sample consisting of 36 760+/-195 D0-->K-pi+ events. We use the observed ratio of D0-->K+pi- to D0-->K-pi+ (0.404+/-0.085+/-0.025)% to obtain a relationship between the D0 mixing and doubly Cabibbo suppressed decay parameters.
Collapse
|
39
|
D'Ambrosi N, Cavaliere F, Merlo D, Milazzo L, Mercanti D, Volonté C. Antagonists of P2 receptor prevent NGF-dependent neuritogenesis in PC12 cells. Neuropharmacology 2000; 39:1083-94. [PMID: 10727719 DOI: 10.1016/s0028-3908(99)00213-0] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The pheochromocytoma PC12 cell line that develops neuronal characteristics of sympathetic cells after treatment with nerve growth factor (NGF) represents a well-established cellular model system for studying NGF signalling. Interesting information on the different mechanistic pathways of NGF can be obtained by adopting the pharmacological approach of inhibiting P2 receptors, expressed in naive PC12 cells and recognised as important biological mediators of neurotransmitters and growth factors. We show here that Basilen Blue, an antagonist of P2 receptor, reversibly prevents NGF-dependent neurite outgrowth with an IC(50) in the 5-10 microM range. Suramin, oxidised-ATP and diisothiocyanatostilbene-disulfonic acid, differently from other purinoceptor ligands, are also effective in this regard. NGF-dependent regeneration and stability of neurites, selected NGF-dependent extracellular and intracellular protein phosphorylations, binding of [(3)H] ATP to PC12 cell membranes are also modulated by Basilen Blue. On the contrary, cell adhesion, cellular duplication, 5'-nucleotidase activity, NGF-induced tyrosine autophosphorylation of TrkA receptors are not affected. NGF furthermore directly modulates the extracellular release of ATP and especially the levels of P2X(2) receptor protein in PC12 cells. In addition, extracellular ATP improves the neuritogenic effect of sub-optimal concentrations of NGF. Our study identifies P2 receptor ligands, particularly Basilen Blue, as useful tools to dissect different NGF-evoked functions, suggesting a mechanistic role for P2 receptors in the signalling pathways of NGF.
Collapse
|
40
|
Rusconi S, De Pasquale MP, Milazzo L, Kurtagic S, Bulgheroni E, Citterio P, Galazzi M, La Seta Catamancio S, Galli M. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther 2000; 3:203-7. [PMID: 10682139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
We examined the in vitro phenotypic and genotypic profiles of an extensively passaged human immunodeficiency virus type 1 clinical isolate which has been selected for lamivudine resistance, with an M184V mutation in a zidovudine-resistant genetic background, and then cultured with zidovudine alone. Our passaging strategy led to a decrease in lamivudine IC50 values, which were comparable to those prior to lamivudine exposure, and the genotypic restoration of the wild-type sequence at codon 184 of reverse transcriptase.
Collapse
|
41
|
Milazzo L, Rusconi S, Testa L, La Seta-Catamancio S, Galazzi M, Kurtagic S, Citterio P, Gianotto M, Grassini A, Adorni F, d'Arminio-Monforte A, Galli M, Moroni M. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine. J Acquir Immune Defic Syndr 1999; 22:101-3. [PMID: 10534153 DOI: 10.1097/00042560-199909010-00013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Abstract
A man with a history of alcohol abuse was admitted to hospital with pneumonia and meningitis due to Streptococcus pneumoniae. Because of the worsening of respiratory function and the persistence of fever, an echocardiographic examination was made, which showed endocarditis with destruction of the aortic valve. The patient underwent surgical valve replacement. In addition, he showed a choroiditis in the left eye which improved after antibiotic therapy. The interest of this case lies in the rarity of the triad described as Austrian's syndrome and in the coexistent fourth septic localization, namely in the left eye.
Collapse
|
43
|
Lorusso GF, De Stasio G, Gilbert B, Perret D, Perfetti P, Margaritondo G, Casalbore P, Ciotti MT, Milazzo L, Mercanti D. High sensitivity quantitative analysis of cobalt uptake in rat cerebellar granule cells with and without excitatory amino acids. Neurosci Lett 1998; 248:9-12. [PMID: 9665651 DOI: 10.1016/s0304-3940(98)00296-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We quantified the effect of the excitatory amino acids kainate and glutamate on the uptake of cobalt in primary rat cerebellar granule neurons, by using inductively coupled plasma-atomic emission spectroscopy (ICP-AES). We quantitatively demonstrated that Co2+ uptake, although enhanced by glutamate and kainate also takes place in the absence of excitatory amino acids. We also found that cobalt uptake is not significantly altered by the presence of glutamate receptor competitive or noncompetitive antagonists, indicating that cobalt uptake in granule neurons does not require glutamate receptor stimulation. Our results suggest, therefore, that Co2+ may enter the cell by passive diffusion through the plasma membrane.
Collapse
|
44
|
Rusconi S, De Pasquale MP, Milazzo L, Bulgheroni E, Citterio P, Kurtagic S, d'Arminio-Monforte A, Galli M. In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate. AIDS 1997; 11:1406-10. [PMID: 9302459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
45
|
Rusconi S, De Pasquale MP, Milazzo L, Moscatelli G, Bulgheroni E, Citterio P, d'Arminio-Monforte A, Moroni M, Galli M. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial. Antivir Ther 1997; 2:39-46. [PMID: 11322265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
In order to compare the resistance pattern to zidovudine plus lamivudine in zidovudine-experienced patients, we studied three HIV-1-infected patients enrolled in NUCB3004, an open-label trial. Over a 24-week follow-up, the patients were studied for drug sensitivity, reverse transcriptase genotype, viral load (HIV-1 RNA level) and viral phenotype (syncytium inducing (SI) or non-syncytium inducing). Virus isolates derived from peripheral blood mononuclear cells (PBMCs) were tested for changes in drug susceptibility. Proviral DNA in the patients' PBMCs and RNA from plasma and culture supernatant were subjected to amplification and sequencing. All three HIV-1 strains showed a decreased susceptibility to either zidovudine or lamivudine after 24 weeks of therapy. The pattern of DNA genotypic resistance to lamivudine in patient A showed a mutation at codon 184 of the reverse transcriptase-encoding gene (methionine to valine). No HIV-1 strains with lamivudine-related mutations in proviral DNA were found among the isolates obtained from patients B and C. In these two patients, the mutation at codon 184 of the reverse transcriptase-encoding gene appeared in RNA, both in plasma and in culture supernatant. Viral phenotyping revealed the maintenance of the SI phenotype at week 24. Two out of the three patients experienced a reduction in HIV-1 RNA levels after 24 weeks of therapy, and in two out of three there was a rebound in viral load at week 28 together with the onset of the codon 184 mutation in RNA. The degree of phenotypic resistance to both zidovudine and lamivudine correlated with the amino acid changes in RNA and the rapid increase in viral load.
Collapse
|
46
|
Milazzo L, Vaira LM, Cremoni L. CD4+ lymphocyte count variations in HIV-negative subjects treated with zidovudine. AIDS 1996; 10:1444-5. [PMID: 8902084 DOI: 10.1097/00002030-199610000-00027] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
47
|
Need JA, Forbes KL, Milazzo L, McKenzie E. Danazol in the treatment of menorrhagia: the effect of a 1 month induction dose (200 mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo). Aust N Z J Obstet Gynaecol 1992; 32:346-52. [PMID: 1290434 DOI: 10.1111/j.1479-828x.1992.tb02849.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
This paper highlights the difficulties of recruiting subjects to objective menstrual blood loss (MBL) studies. Such difficulties may explain the relative paucity of such studies in the literature. Eleven women with objectively assessed evidence of menorrhagia were treated for 1 month with an induction dose of 200 mg of danazol (Danocrine). Subsequently the women were randomly assigned to receive 50, 100 or 200 mg of danazol or placebo for 2 months of maintenance dosing. Follow-up with objective assessment of MBL was continued for 3 months after cessation of maintenance dosing. Danazol 200 mg as an induction dose significantly reduced MBL. The maintenance dose of 200 mg during the following 2 months produced a further decrease in MBL and in some cases amenorrhoea. The lower maintenance dosages of 50 mg and 100 mg were associated with a variable response. The study was unable to determine whether any beneficial effect of the maintenance dosages of danazol could be maintained following cessation of therapy since the study numbers had become too small. It appears, however, that there is unlikely to be any persisting benefit once therapy has ceased.
Collapse
|
48
|
Puglisi G, Caruso A, Milazzo L, Marchetta G, Mazzone G, Amico-Roxas M, Vanella A. [Anti-inflammatory activity in dermatologic formulations of 3-carboxymethylthiotriazoles]. BOLLETTINO CHIMICO FARMACEUTICO 1983; 122:374-83. [PMID: 6661297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
49
|
Mazzone G, Bonina F, Puglisi G, Milazzo L, Arrigo Reina R, Cosentino C. [The synthesis of some 5-aryl-2-amino-1,3,4-oxadiazoles and thiadiazoles and preliminary pharmacologic research]. BOLLETTINO CHIMICO FARMACEUTICO 1983; 122:130-6. [PMID: 6334532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
50
|
Giovinazzo C, Puglisi G, Milazzo L, Caruso A, Mazzone G, Bernardini A. [Stability of tablet formulation containing erythromycin ethylsuccinate and demeclocycline hydrochloride]. BOLLETTINO CHIMICO FARMACEUTICO 1983; 122:109-17. [PMID: 6409133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|